Glucuronidation in therapeutic drug monitoring

被引:46
|
作者
Shipkova, M
Wieland, E
机构
[1] Klinikum Stuttgart, Zentralinst Klin Chem & Laboratoriumsmed, D-70174 Stuttgart, Germany
[2] Klinikum Stuttgart, Dept Clin Chem & Lab Med, D-70174 Stuttgart, Germany
关键词
glucuronide metabolites; drug monitoring; UGT polymorphisms; drug pharmacokinetic; pharmacologically active metabolites; toxicity;
D O I
10.1016/j.cccn.2005.02.023
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Glucuronidation is a major drug-metabolizing reaction in humans. A pharmacological effect of glucuronide metabolites is frequently neglected and the value of therapeutic drug Monitoring has been questioned, However, this may not always be true. Methods: In this review the impact of glucuronidation on therapeutic drug monitoring, has been evaluated on the basis of a literature search and experience from the own laboratory. Results: The potential role of monitoring glucuronide metabolite concentrations to optimize therapeutic Outcome is addressed on the basis of selected examples of drugs which are metabolized to biologically active reactive glucuronides, Furthermore indirect effects of glucuronide metabolites on parent drug. pharmacokinetics are presented. In addition, factors that may modulate the disposition of these metabolites (e.g. genetic polymorphisms, disease processes, age, and drug drug interactions) are briefly mentioned and their relevance for the clinical Situation is critically discussed. Conclusion: Glucuronide metabolites can have indirect as well as direct pharmacological or toxicological effects. Although convincing evidence to support the introduction Of glucuronide monitoring into clinical practice is currently missing, measurement of glucuronide concentrations may be advantageous in specific situations, If the glucuronide metabolite has an indirect effect on the pharmacokinetics of the parent compound, monitoring of the parent drug may be considered. Furthermore pharmacogenetic approaches considering uridine diphosphate (UDP) glucuronosyltransferases polymorphisms may become useful in the future to optimize therapy with drugs Subject to glucuronidation. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:2 / 23
页数:22
相关论文
共 50 条
  • [1] Therapeutic drug monitoring in drug overdose
    Dawson, AH
    Whyte, IM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (03) : 278 - 283
  • [2] Therapeutic drug monitoring in drug overdose
    Dawson, AH
    Whyte, IM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 : 97S - 102S
  • [3] Therapeutic drug monitoring for immunosuppressants
    Wong, SHY
    CLINICA CHIMICA ACTA, 2001, 313 (1-2) : 241 - 253
  • [4] Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations
    Hertz, Daniel L.
    Joerger, Markus
    Bang, Yung-Jue
    Mathijssen, Ron H.
    Zhou, Caicun
    Zhang, Li
    Gandara, David
    Stahl, Michael
    Monk, Bradley J.
    Jaehde, Ulrich
    Beumer, Jan H.
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [5] Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range
    Abdul-Aziz, Mohd H.
    Brady, Kara
    Cotta, Menino Osbert
    Roberts, Jason A.
    THERAPEUTIC DRUG MONITORING, 2022, 44 (01) : 19 - 31
  • [6] Therapeutic Drug Monitoring of Mycophenolic Acid
    Dasgupta, A.
    ADVANCES IN CLINICAL CHEMISTRY, VOL 76, 2016, 76 : 165 - 184
  • [7] Issues in therapeutic drug monitoring validation
    Paintaud, G
    Le Guellec, C
    Furet, Y
    Autret-Leca, E
    THERAPIE, 2001, 56 (03): : 245 - 249
  • [8] Therapeutic drug monitoring of antifungal agents
    Heinz, Werner J.
    Klinker, Hartwig
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2012, 36 (02): : 99 - 109
  • [9] Therapeutic drug monitoring in clinical research
    Neef C.
    Touw D.J.
    Stolk L.M.
    Pharmaceutical Medicine, 2008, 22 (4) : 235 - 244
  • [10] ECONOMIC ISSUES IN THERAPEUTIC DRUG MONITORING
    Petryszyn, Pawel
    Wiela-Hojenska, Anna
    ACTA POLONIAE PHARMACEUTICA, 2016, 73 (03): : 599 - 604